Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale to target TROP-2 in lung cancer.

TROP2 is a transmembrane glycoprotein that is involved in intracellular calcium signaling transduction and facets of tumorigenesis, including proliferation and metastasis, Skoulidis explains. Notably, TROP2 is overexpressed across a range of cancer types, including lung adenocarcinoma and squamous cell lung carcinoma, Skoulidis adds. As such, TROP2-directed treatments could offer a new generation of precision medicine–based lung cancer treatment. 

Findings from the ongoing phase 1 TROPION-PanTumor01 trial (NCT03401385), which were presented during the 

, demonstrated encouraging clinical efficacy with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (dato-DXd; DS-1062a) in patients with relapsed/refractory advanced or metastatic non–small cell lung cancer. At the dosing regimen of 6 mg/kg every 3 weeks, dato-DXd elicited an overall response rate of 26% and a median duration of response of 10.5 months in these patients, many of whom received prior immunotherapy and chemotherapy, Skoulidis concludes.

Videos

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.   



Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer 

Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of a subgroup analysis from the phase 2 CodeBreaK 100 trial (NCT03600883) in patients with 

 G12C-mutant non–small cell lung cancer (NSCLC). 

Findings from the registrational CodeBreaK 100 study demonstrated a 37.1% objective response rate (ORR) with sotorasib (Lumakras) in patients with pretreated 

 G12C-mutant NSCLC. The median progression-free survival was 6.8 months. Notably, based on these findings, sotorasib was approved by the FDA on May 28, 2021, for the treatment of patients with 

 G12C-mutated NSCLC who have received at least 1 prior systemic therapy. 

During the 2021 ASCO Annual Meeting, overall survival (OS) data and exploratory subgroup analyses from the CodeBreaK 100 trial were presented virtually. The results revealed a median overall survival of 12.5 months with sotorasib. Additionally, sotorasib demonstrated efficacy across various prespecified patient and molecular subgroups. Notably, sotorasib was effective in patients whose tumors harbored 

 mutations, which is a population that has inferior outcomes with standard therapies, concludes Skoulidis. 

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer. 










Dr. Skoulidis on the Results of Subgroup Analyses of the CodeBreaK 100 Trial in KRAS G12C-Mutant NSCLC 

Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non—small cell lung cancer (NSCLC).

The KEYNOTE-021 data suggested a combination of pembrolizumab (Keytruda) with carboplatin/pemetrexed was associated with a 55% objective response rate, almost more than a chemotherapy doublet alone.

Combining chemotherapy with immunotherapy benefited PD-L1—negative tumors and has an additive effect, so it would be a valid treatment option for patients who express low levels of PD-L1, explains Skoulidis.

Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non-small cell lung cancer (NSCLC).

Ferdinandos Skoulidis, MD, PhD, MRCP

Articles

Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer

Dr. Skoulidis on the Results of Subgroup Analyses of the CodeBreaK 100 Trial in KRAS G12C-Mutant NSCLC

Dr. Skoulidis on Combining Chemotherapy and Immunotherapy in NSCLC